Semin Musculoskelet Radiol 2002; 06(3): 207-218
DOI: 10.1055/s-2002-36718
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Dual Energy X-Ray Absorptiometry and Its Clinical Applications

Glen M. Blake, Ignac Fogelman
  • Guy's, King's and St Thomas' School of Medicine, St Thomas Street, London, United Kingdom
Further Information

Publication History

Publication Date:
23 January 2003 (online)

ABSTRACT

Bone density scans using the technique of dual energy X-ray absorptiometry (DXA) are widely seen as having an essential role in the evaluation of patients at risk of osteoporosis. DXA scans of the spine and hip are the most useful because fractures at these sites result in the greatest impairment of quality of life. A hip DXA scan is the most reliable way of evaluating hip fracture risk, and the spine is the most sensitive site for monitoring response to treatment. Fundamental to the clinical role of DXA scanning are the findings of epidemiological studies that relate fracture risk to bone mineral density. The results of spine and hip DXA scans are interpreted using the World Health Organisation (WHO) definition of osteoporosis as a T-score less than -2.5. DXA scans are also used in longitudinal studies, both for research studies and for follow-up scans of individual patients. Although the former have an important role in the development of new treatments for osteoporosis, the latter are more controversial and are likely to be less important in the future. There is also interest in the use of smaller, less expensive DXA systems for scanning sites in the peripheral skeleton. However, in general, the results from these devices cannot be interpreted using the WHO definition of osteoporosis, and until there is a consensus over establishing an equivalent threshold, their use is premature.

REFERENCES

  • 1 Genant H K, Engelke K, Fuerst T. Noninvasive assessment of bone mineral and structure: state of the art.  J Bone Miner Res . 1996;  11 707-730
  • 2 Baran D T, Faulkner K G, Genant H K. Diagnosis and management of osteoporosis: guidelines for the utilization of bone densitometry.  Calcif Tissue Int . 1997;  61 433-440
  • 3 Kanis J A, Delmas P, Burckhardt P, Cooper C, Torgerson D. on behalf of the European Foundation for Osteoporosis and Bone Disease. Guidelines for diagnosis and treatment of osteoporosis.  Osteoporos Int . 1997;  7 390-406
  • 4 Cooper C, Campion G, Melton L J. Hip fractures in the elderly; a world-wide projection.  Osteoporos Int . 1992;  2 285-289
  • 5 Schurch M-A, Rizzoli R, Mermillod B. A prospective study on socio-economic aspects of fracture of the proximal femur.  J Bone Miner Res . 1996;  11 1935-1942
  • 6 Ray N F, Chan J K, Thamer M, Melton L J. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995; report from the National Osteoporosis Foundation.  J Bone Miner Res . 1997;  12 24-35
  • 7 Black D M, Cummings S R, Karpf D B. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures.  Lancet . 1996;  348 1535-1541
  • 8 Ettinger B, Black D M, Mitlak B H. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.  JAMA . 1999;  282 637-645
  • 9 Harris S T, Watts N B, Genant H K. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.  JAMA . 1999;  282 1344-1352
  • 10 Neer R M, Arnaud C D, Zanchetta J R. Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis.  N Engl J Med . 2001;  344 1434-1441
  • 11 Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis.  Am J Med . 1993;  94 646-650
  • 12 WHO Technical Report Series 843. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis Geneva: World Health Organization; 1994
  • 13 Heaney R P, Abrams S, Dawson-Hughes B. Peak bone mass.  Osteoporos Int . 2000;  11 985-1009
  • 14 Guglielmi G. Quantitative computed tomography.  Semin Musculoskeletal Radiol . 2002;  6 219-228
  • 15 Stewart A, Reid D. Quantitative ultrasound in osteoporosis.  Semin Musculoskeletal Radiol . 2002;  6 229-232
  • 16 Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.  Br Med J . 1996;  312 1254-1259
  • 17 Cummings S R, Black D M, Nevitt M C. Bone density at various sites for prediction of hip fractures.  Lancet . 1993;  341 72-75
  • 18 Black D M, Palermo L, Bauer D. How well does bone mass predict long-term risk of hip fracture (Abst)?.  Osteoporos Int. . 2000;  11(Suppl 2) S59
  • 19 Eastell R. Treatment of postmenopausal osteoporosis.  N Engl J Med . 1998;  338 736-746
  • 20 Njeh C F, Fuerst T, Hans D, Blake G M, Genant H K. Radiation exposure in bone mineral assessment.  Appl Rad Isotope . 1999;  50 215-236
  • 21 Blake G M, Herd R MJ, Patel R, Fogelman I. The effect of weight change on total body dual energy x-ray absorptiometry: results from a clinical trial.  Osteoporos Int . 2000;  11 832-839
  • 22 Bouxsein M L, Parker R A, Greenspan S L. Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women.  Osteoporos Int . 1999;  10 505-509
  • 23 Svendsen O L, Hassager C, Skodt V, Christiansen C. Impact of soft tissue on in-vivo accuracy of bone mineral measurements in the spine, hip, and forearm: a human cadaver study.  J Bone Miner Res . 1995;  10 868-873
  • 24 Boudousq V, Kotzki P O, Dinten J M. Radiation dose assessment on patients and staff from a new 2D digital bone densitometer (in press).  Osteoporos Int.
  • 25 Cameron J R, Sorensen J A. Measurement of bone mineral in vivo: an improved method.  Science . 1963;  142 230-232
  • 26 Düppe H, Gärdsell P, Nilsson B, Johnell O. A single bone density measurement can predict fractures over 25 years.  Calcif Tissue Int . 1997;  60 171-174
  • 27 Patel R, Blake G M, Fogelman I. Radiation dose to the patient and operator from a peripheral dual x-ray absorptiometry system.  J Clin Densitom . 1999;  2 397-401
  • 28 Faulkner K G, VonStetton E, Miller P. Discordance in patient classification using T-scores.  J Clin Densitom . 1999;  2 343-350
  • 29 Black D M. Revision of T-score BMD diagnostic thresholds (Abst).  Osteoporosis Int . 2000;  11(Suppl 2) S58
  • 30 Blake G M, Knapp K M, Fogelman I. Absolute fracture risk varies with bone densitometry technique used: a theoretical and in-vivo study of fracture cases.  J Clin Densitom . 2002;  5 109-116
  • 31 Liberman U A, Weiss S R, Bröll J. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.  N Engl J Med . 1995;  333 1437-1443
  • 32 Tonino R P, Meunier P J, Emkey R. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women.  J Clin Endocrinol Metab . 2000;  85 3109-3115
  • 33 Cummings S R, Black D M, Thompson D E. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: results from the Fracture Intervention Trial.  JAMA . 1998;  280 2077-2082
  • 34 Reginster J-Y, Minne H W, Sorensen O H. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.  Osteoporos Int . 2000;  11 83-91
  • 35 Chesnut C H, Silverman S, Andriano K. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study.  Am J Med . 2000;  109 267-276
  • 36 McClung M R, Geusens P, Miller P D. Effect of risedronate treatment on hip fracture risk in elderly women.  N Engl J Med . 2001;  344 333-340
  • 37 Reid I R, Brown J P, Burckhardt P. Intravenous zolendronic acid in postmenopausal women with low bone mineral density.  N Engl J Med . 2002;  346 653-661
  • 38 Cummings S R, Palermo L, Browner W. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean.  JAMA . 2000;  283 1318-1321
  • 39 Blake G M, Fogelman I. Peripheral or central densitometry: does it matter which technique we use?.  J Clin Densitom . 2001;  4 83-96
  • 40 Altman D G. Practical Statistics for Medical Research.  London: Chapman Hall; 1991
  • 41 Cummings S R, Black D M, Nevitt M C. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group.  JAMA . 1990;  263 665-668
  • 42 Seeley D G, Browner W S, Nevitt M C. Which fractures are associated with low appendicular bone mass in elderly women?.  Ann Intern Med . 1991;  115 837-842
  • 43 Siris E S, Miller P D, Barrett-Connor M D. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.  JAMA . 2001;  286 2815-2822
  • 44 Faulkner K, Abbott T A, Furman W D. Fracture risk assessment in NORA is comparable across peripheral sites (Abst).  J Bone Miner Res . 2000;  15(Suppl 1) S144
  • 45 Faulkner K G, Roberts L A, McClung M R. Discrepancies in normative data between Lunar and Hologic DXA systems.  Osteoporos Int . 1996;  6 432-436
  • 46 Hanson J. Standardization of femur BMD (Letter).  J Bone Miner Res . 1997;  12 1316-1317.
  • 47 Looker A C, Wahner H W, Dunn W L. Updated data on proximal femur bone mineral levels of US adults.  Osteoporos Int . 1998;  8 468-489
  • 48 Chen Z, Maricic M, Lund P, Tesser J, Gluck O. How the new Hologic hip reference values affect the densitometric diagnosis of osteoporosis.  Osteoporos Int . 1998;  8 423-427
  • 49 Genant H K, Grampp S, Glüer C-C. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results.  J Bone Miner Res . 1994;  9 1503-1514
  • 50 Steiger P. Standardization of spine BMD (Letter).  J Bone Miner Res . 1995;  10 1602-1603
  • 51 National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis.  Osteoporos Int . 1998;  8(Suppl 4) S7-S80
  • 52 Royal College of Physicians. Osteoporosis: Clinical Guidelines for Prevention and Treatment London: Royal College of Physicians; 1999
  • 53 National Osteoporosis Foundation. Physicians Guide to Prevention and Treatment of Osteoporosis Washington, DC: National Osteoporosis Foundation; 1998
  • 54 Royal College of Physicians. Osteoporosis: Clinical Guidelines for Prevention and Treatment. Update on Pharmacological Interventions and an Algorithm for Management. London: Royal College of Physicians; 2000
  • 55 Kanis J A, Glüer C-C. An update on the diagnosis and assessment of osteoporosis with densitometry.  Osteoporos Int . 2000;  11 192-202
  • 56 Glüer C-C, Blake G, Lu Y. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques.  Osteoporos Int . 1995;  5 262-270
  • 57 Patel R, Blake G M, Rymer J, Fogelman I. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women.  Osteoporos Int . 2000;  11 68-75
  • 58 Hoskings D, Chilvers C E, Christiansen C. Prevention of bone loss in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group.  N Engl J Med . 1998;  338 485-492
  • 59 Faulkner K G. Bone densitometry: choosing the proper skeletal site to measure.  J Clin Densitom . 1998;  1 279-285
  • 60 Blake G M, Herd R JM, Fogelman I. A longitudinal study of supine lateral DXA of the lumbar spine: a comparison with posteroanterior spine, hip and total body DXA.  Osteoporos Int . 1996;  6 462-470